Online inquiry

IVTScrip™ mRNA-Anti-EGFR, cetuximab-IR700(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5791MR)

This product GTTS-WQ5791MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, cetuximab-IR700(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ5791MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ3998MR IVTScrip™ mRNA-Anti-PDCD1, BGB-A317(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BGB-A317
GTTS-WQ14704MR IVTScrip™ mRNA-Anti-SELP, SEG101(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SEG101
GTTS-WQ1327MR IVTScrip™ mRNA-Anti-MET, ABT-700(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABT-700
GTTS-WQ12075MR IVTScrip™ mRNA-Anti-CD19, MOR-00208(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MOR-00208
GTTS-WQ4952MR IVTScrip™ mRNA-Anti-GP, c13C6-FR1-N(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA c13C6-FR1-N
GTTS-WQ5680MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CDX-011 (DOX)
GTTS-WQ8498MR IVTScrip™ mRNA-Anti-ITGAL, hu1124(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA hu1124
GTTS-WQ11346MR IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MEDI-551
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW